Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise over 29% on the day. The upside has been driven by positive top-line results from ETC-1002-009, a Phase 2b study evaluating the efficacy and safety of ETC-1002 (bempedoic acid) in comparison to placebo in patients with hypercholesterolemia on stable statin therapy. This led to more shares changing hands than in a normal session. Yesterday’s rally continues the uptrend for the company since Mar 5, as the stock is now up almost 58%.
Over the last 30 days, this company witnessed one negative estimate revision and the Zacks Consensus Estimate also moved lower, suggesting trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.
Esperion Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the med-drugs industry may also consider Lannett Company, Inc. (LCI) which sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment